Edwards Lifesciences Corp (EW)vsHaemonetics Corporation (HAE)
EW
Edwards Lifesciences Corp
$93.26
+1.36%
HEALTHCARE · Cap: $52.90B
HAE
Haemonetics Corporation
$120.28
+0.12%
HEALTHCARE · Cap: $5.38B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 382% more annual revenue ($6.51B vs $1.35B). EW leads profitability with a 15.4% profit margin vs 7.1%. HAE appears more attractively valued with a PEG of 1.90. EW earns a higher WallStSmart Score of 53/100 (C-).
EW
Buy53
out of 100
Grade: C-
HAE
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.5%
Fair Value
$251.45
Current Price
$93.26
$158.19 discount
Margin of Safety
+34.3%
Fair Value
$87.57
Current Price
$120.28
$32.71 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Strong operational efficiency at 29.8%
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Expensive relative to growth rate
2.9% earnings growth
Distress zone — elevated risk
7.1% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : HAE
HAE has a balanced fundamental profile.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 54.6x leaves little room for execution misses.
Bear Case : HAE
The primary concerns for HAE are PEG Ratio, EPS Growth, Altman Z-Score. A P/E of 57.2x leaves little room for execution misses.
Key Dynamics to Monitor
EW profiles as a mature stock while HAE is a value play — different risk/reward profiles.
EW carries more volatility with a beta of 0.86 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (53/100 vs 50/100), backed by strong 15.4% margins and 13.6% revenue growth. HAE offers better value entry with a 34.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?